Concorde Asset Management, LLC - CRISPR THERAPEUTICS AG ownership

CRISPR THERAPEUTICS AG's ticker is CRSP and the CUSIP is H17182108. A total of 471 filers reported holding CRISPR THERAPEUTICS AG in Q3 2021. The put-call ratio across all filers is 1.71 and the average weighting 0.2%.

Quarter-by-quarter ownership
Concorde Asset Management, LLC ownership history of CRISPR THERAPEUTICS AG
ValueSharesWeighting
Q3 2021$535,000
+118.4%
4,782
+215.6%
0.31%
+123.9%
Q2 2021$245,000
-29.2%
1,515
-46.7%
0.14%
-30.7%
Q1 2021$346,000
-84.6%
2,845
-80.7%
0.20%
-84.1%
Q4 2020$2,253,000
+171.4%
14,712
+48.3%
1.25%
+164.1%
Q3 2020$830,0009,9210.47%
Other shareholders
CRISPR THERAPEUTICS AG shareholders Q3 2021
NameSharesValueWeighting ↓
Versant Venture Management, LLC 498,558$31,294,00031.24%
NEA Management Company, LLC 1,590,002$365,593,00010.56%
Ariose Capital Management Ltd 37,900$2,379,0009.30%
ARK Investment Management 9,404,071$590,294,0002.46%
NIA IMPACT ADVISORS, LLC 80,082$5,027,0002.44%
Nikko Asset Management Americas, Inc. 4,619,747$291,044,0002.14%
PLUSTICK MANAGEMENT LLC 50,000$3,139,0001.98%
Integral Health Asset Management, LLC 120,000$7,532,0001.96%
Valiant Capital Management, L.P. 240,683$15,108,0001.73%
Deuterium Capital Management, LLC 18,000$1,130,0001.45%
View complete list of CRISPR THERAPEUTICS AG shareholders